Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5955
    +0.0005 (+0.09%)
     
  • NZD/EUR

    0.5546
    +0.0006 (+0.10%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    83.82
    +0.25 (+0.30%)
     
  • GOLD

    2,360.80
    +18.30 (+0.78%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,110.77
    +31.91 (+0.39%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,039.95
    +122.67 (+0.68%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.2170
    +0.7210 (+0.78%)
     

More Likely to 5x First: Novavax vs. Ocugen

More Likely to 5x First: Novavax vs. Ocugen

Biotech companies are ripe with innovation. The two stocks I'll talk about here -- Novavax (NASDAQ: NVAX) and Ocugen (NASDAQ: OCGN) -- both have soared in recent years on optimism about potentially game-changing products. Novavax soared more than 2,700% in 2020 as investors bet on its investigational coronavirus vaccine.